Physcion increases the sensitivity of hepatocellular carcinoma to sorafenib through miRNA-370/PIM1 axis-regulated glycolysis

Figure 3 Physcion promotes the inhibition of sorafenib on hepatocellular carcinoma glycolysis. The sorafenib-resistant Huh7-SR and HepG2-SR cells were treated with physcion and/or sorafenib. A-D: Glucose uptake (A), lactate production (B), extracellular acidification rate (C and D); E and F: Oxygen consumption rate. ^aP < 0.05, ^bP < 0.001 versus control (Cont) group; ^cP < 0.001 versus Cont + SF group. Cont: Control; SF: Sorafenib; phy: Physcion; ECAR: Extracellular acidification rate; OCR: Oxygen consumption rate.